Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IBIO Stock Forecast 2026-2027
$1.82
Current Price
$85.94M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IBIO Price Targets
+284.6%
To High Target of $7.00
+229.7%
To Median Target of $6.00
+130.8%
To Low Target of $4.20
IBIO Price Momentum
+3.4%
1 Week Change
+6.4%
1 Month Change
+100.0%
1 Year Change
-5.7%
Year-to-Date Change
-52.4%
From 52W High of $3.82
+225.0%
From 52W Low of $0.56
📊 TOP ANALYST CALLS
Did IBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if iBio is one of their latest high-conviction picks.
Latest IBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IBIO has a bullish consensus with a median price target of $6.00 (ranging from $4.20 to $7.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.82, the median forecast implies a 229.7% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IBIO Analyst Ratings
7
Buy
0
Hold
0
Sell
IBIO Price Target Range
Low
$4.20
Average
$6.00
High
$7.00
Current: $1.82
Latest IBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Mar 18, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Jones Trading | Buy | Initiates | $N/A | |
| Feb 12, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Oct 21, 2025 | Oppenheimer | Outperform | Initiates | $N/A | |
| Oct 17, 2025 | Leerink Partners | Outperform | Initiates | $N/A | |
| Jun 25, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 6, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 5, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | Buy | Initiates | $N/A | |
| Jul 22, 2024 | Brookline Capital | Buy | Initiates | $N/A | |
| Jun 3, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| May 28, 2024 | Chardan Capital | Buy | Initiates | $N/A | |
| Feb 16, 2023 | JMP Securities | Roy Buchanan | Market Perform | Downgrade | $N/A |
| Oct 7, 2022 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $0.17 |
| Nov 29, 2021 | JMP Securities | Roy Buchanan | Outperform | Initiates | $1.50 |
| Jan 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Jan 21, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Jun 26, 2020 | Alliance Global Partners | Buy | Initiates | $N/A |
iBio, Inc. (IBIO) Competitors
The following stocks are similar to iBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
iBio, Inc. (IBIO) Financial Data
iBio, Inc. has a market capitalization of $85.94M with a P/E ratio of 0.6x. The company generates $300,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -9,653.0% and return on equity of -62.1%.
Valuation Metrics
Market Cap
$85.94M
Enterprise Value
$17.94M
P/E Ratio
0.6x
PEG Ratio
0.0x
Price/Sales
301.4x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-9,653.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+82.7%
Current Ratio
11.9x
Debt/Equity
3.0x
ROE
-62.1%
ROA
-34.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
iBio, Inc. (IBIO) Business Model
About iBio, Inc.
What They Do
Develops next-generation biopharmaceuticals using AI.
Business Model
iBio Inc. operates as a preclinical-stage biotechnology company, focusing on the development of novel antibody-based therapies for various diseases, including cancer and cardiometabolic conditions. The company generates revenue by advancing its proprietary technology platforms, which enhance the design and optimization of antibodies through artificial intelligence, enabling them to target previously undruggable proteins.
Additional Information
iBio's pipeline includes promising candidates such as IBIO-101 for solid tumors and a collaboration with AstralBio to develop therapies for obesity. Founded in 2008 and based in San Diego, California, iBio aims to transform drug discovery processes and expedite the timeline for bringing precision medicine to market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
20
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Country
United States
IPO Year
2008
Website
ibioinc.comiBio, Inc. (IBIO) Latest News & Analysis
Latest News
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. (NASDAQ: IBIO) announced CEO Martin Brenner and CFO Felipe Duran will present at the Jefferies Global Healthcare Conference and the Leerink Partners Forum focusing on therapeutics.
Why It Matters
iBio's participation in key healthcare conferences highlights its commitment to innovation and visibility in the market, potentially impacting investor perception and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. received regulatory approval for its Phase 1 trial of IBIO-600 in Australia and expanded its pipeline into PH-HFpEF. They reported positive preclinical data for IBIO-610 and shared Q3 financial results.
Why It Matters
Regulatory clearance for Phase 1 trials and positive preclinical results can enhance iBio's market position, boost investor confidence, and potentially increase stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
2 months ago
Quick Summary
iBio, Inc. announced that IBIO-600, an anti-myostatin monoclonal antibody, has received approval to start a Phase 1 clinical trial in Australia, with first dosing expected in Q2 2026.
Why It Matters
The approval of IBIO-600's clinical trial enhances iBio's growth prospects, potentially leading to breakthrough treatments in obesity, impacting market valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. (IBIO) presented details on its bispecific antibody program, focusing on its strategy to address pulmonary hypertension in heart failure.
Why It Matters
iBio's focus on bispecific antibodies for pulmonary hypertension in heart failure could signal innovation and potential market opportunities, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company will hold a corporate update call on Tuesday, March 17, at 4 p.m. ET.
Why It Matters
The corporate update call may provide insights into the company's performance, strategic direction, and future prospects, influencing investor sentiment and stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IBIO Stock
What is iBio, Inc.'s (IBIO) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, iBio, Inc. (IBIO) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $4.20.
Is IBIO stock a good investment in 2026?
According to current analyst ratings, IBIO has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IBIO stock?
Wall Street analysts predict IBIO stock could reach $6.00 in the next 12 months. This represents a 229.7% increase from the current price of $1.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is iBio, Inc.'s business model?
iBio Inc. operates as a preclinical-stage biotechnology company, focusing on the development of novel antibody-based therapies for various diseases, including cancer and cardiometabolic conditions. The company generates revenue by advancing its proprietary technology platforms, which enhance the design and optimization of antibodies through artificial intelligence, enabling them to target previously undruggable proteins.
What is the highest forecasted price for IBIO iBio, Inc.?
The highest price target for IBIO is $7.00 from at , which represents a 284.6% increase from the current price of $1.82.
What is the lowest forecasted price for IBIO iBio, Inc.?
The lowest price target for IBIO is $4.20 from at , which represents a 130.8% increase from the current price of $1.82.
What is the overall IBIO consensus from analysts for iBio, Inc.?
The overall analyst consensus for IBIO is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are IBIO stock price projections?
Stock price projections, including those for iBio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 1:10 AM UTC